Nanjing Vcare Listed in Top 20 of 2026 China Outstanding CRO Brand Ranking

2026-05-13

　　From May 13 to 15, the 94th API China and the 92nd PHARMCHINA were held concurrently in Shanghai. On the opening day, the authoritative industry list 2026 China Outstanding CRO Brand Ranking was officially released. Relying on its outstanding comprehensive strength, profound technological accumulation and strong brand momentum, Nanjing Vcare PharmaTech Co., Ltd. (Nanjing Vcare) was honorably selected into the Top 20 list, further demonstrating its steady brand influence and extensive market recognition in the field of pharmaceutical R&D services.

　　The selection system of this year's China Outstanding CRO Brand Ranking is rigorous and scientific. Centering on ten core indicators including annual total revenue, R&D investment, staff scale, brand popularity, technological innovation capability, customer satisfaction, project delivery capacity, industry influence, compliance operation level and growth potential, it conducts a comprehensive, objective and fair evaluation of the comprehensive strength of domestic CRO enterprises through multi-dimensional analysis based on big data models and joint review by authoritative industry experts. The selection results are of high gold content and serve as an important benchmark for measuring enterprises' industry status and core competitiveness. This honor is not only high recognition from the industry for Nanjing Vcare’s years of dedication to the whole industrial chain of pharmaceutical R&D and production services as well as adherence to innovation-driven development, but also full affirmation of the Company’s continuous efforts in strengthening technological capabilities, optimizing the service system and achieving high-quality development.

　　As a one-stop CRO/CDMO service platform integrating Chemistry + Pharmaceutics + Medicine, Nanjing Vcare has always focused on the whole industrial chain and full life-cycle R&D and production services for chemical drugs since its establishment. It has built core technology platforms covering flow chemistry, bioenzymatic catalysis, photochemistry and more, and assembled a highly educated and high-caliber R&D technical team. With professional technical expertise, strict quality control and efficient project delivery, the Company provides differentiated R&D and production services for global pharmaceutical enterprises and new drug R&D institutions, empowering the innovation and development of pharmaceutical research.

Prev

Full-industry Chain Services Empower Drug R&D! Nanjing Vcare Shines at the 94th API China & 92nd PHARMCHINA

Next

Nanjing Vcare Approved to Establish Jiangsu Provincial Postdoctoral Innovation Practice Base